Search - tctmd.com

Displaying 101 - 120 of 159

Sort: Relevancy | Date

Presentation TCT 2017

Should Alleviating ISCHEMIA Be the Goal?

Presenter: Bernard J. Gersh, Robert A. Harrington, David J. Moliterno

October 30, 2017

Presentation TCT 2017

Primary Prevention in High Risk Patients II: THEMIS

Presenter: Bernard J. Gersh, Robert A. Harrington

October 30, 2017

Presentation TCT 2017

Primary Prevention In High Risk Patients I: REPRIEVE

Presenter: Bernard J. Gersh, Robert A. Harrington, Pamela S. Douglas

October 30, 2017

Presentation TVT 2017

Device Design Features and Findings From the Meta-Analysis of Three Randomized Clinical Trials

Presenter: Axel Linke

June 15, 2017

Presentation JIM 2017

Perspectives on the ABSORB Randomized Trials: Take-home Messages for the Clinical Practitioner

Presenter: Gregg W. Stone

February 08, 2017

Presentation TCT 2016

ILLUMENATE U.S.: A Prospective, Randomized Trial of a Paclitaxel-Coated Balloon vs an Uncoated Balloon for Treatment of Diseased Superficial Femoral and Popliteal Arteries

Presenter: Martin B. Leon, Louis A. Cannon, Sean P. Lyden

November 02, 2016

Presentation TCT 2016

What Do the Randomized Clinical Trials Tell Us and How Did the FDA Respond?

Presenter: John D. Carroll, Christian Spies

November 01, 2016

Presentation TCT 2016

PARTNER II QUALITY OF LIFE: Health Status Benefits From a Prospective, Randomized Trial of Transcatheter and Surgical Aortic Valve Replacement in Intermediate-Risk Patients With Severe Aortic Stenosis

Presenter: Gregg W. Stone, Philippe Pibarot, David J. Cohen

November 01, 2016

Presentation TCT 2016

SENTINEL: A Prospective, Randomized Trial Evaluating Cerebral Protection in Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement

Presenter: Gregg W. Stone, Philippe Pibarot, Susheel K. Kodali

November 01, 2016

Presentation TCT 2016

Observational vs Randomized Trials: Strengths and Weaknesses (With Case Examples)

Presenter: Stuart J. Pocock, Jan G. P. Tijssen, Usman Baber

November 01, 2016

Presentation TCT 2016

TCT 60: Clinical Outcomes of Absorb Bioresorbable Vascular Scaffold (BVS) in Diabetic and Non-Diabetic Patients: Patient-Level Pooled Analysis From the ABSORB Randomized Trials

Presenter: Antonio L. Bartorelli, Kenneth Chin, Ariel Furer

October 31, 2016

Presentation TCT 2016

TCT 65: Comparative Efficacy and Safety of Coronary Stents in Diabetic Patients With and Without Insulin Treatment: A Pooled Patient Level Analysis From 17 Randomized Trials

Presenter: Sorin J. Brener, Jean-François Tanguay, Jaya Chandrasekhar

October 31, 2016

Presentation TCT 2016

NOBLE: A Prospective, Randomized Trial Comparing Biolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients With Left Main Coronary Artery Disease

Presenter: Martin B. Leon, Keith G. Oldroyd, Evald H. Christiansen

October 31, 2016

Presentation TCT 2016

EXCEL: A Prospective, Randomized Trial Comparing Everolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients With Left Main Coronary Artery Disease

Presenter: Martin B. Leon, Keith G. Oldroyd, Gregg W. Stone

October 31, 2016

Presentation TCT 2016

When Are Randomized Trials Not Enough, and Can Observational Data Reliably Inform Comparative Effectiveness Decisions?

Presenter: Eugene H. Blackstone, Robert W. Yeh, Robert A. Harrington

October 30, 2016

Presentation TCT 2016

Can Propensity and Instrumental Variable Methods Overcome the Limitations of Observational Databases: Lessons From TRANSLATE-ACS

Presenter: Eugene H. Blackstone, Robert W. Yeh, Tracy Y. Wang

October 30, 2016

Presentation TCT 2016

Comparison of Propensity Score Methods and Covariate Adjustment in Observational Studies: Similarities and Differences

Presenter: Eugene H. Blackstone, Robert W. Yeh, Stuart J. Pocock

October 30, 2016

Presentation TCT 2016

Importance of Unmeasured Confounders in Observational Registries: ASCERT and Other Examples

Presenter: Eugene H. Blackstone, Robert W. Yeh, Kirk N. Garratt

October 30, 2016

Presentation TCT 2016

The Smoker's Paradox Revisited: A Five-Year Patient-Level Pooled Analysis of 17 Randomized Controlled Trials

Presenter: Mayank Yadav

October 30, 2016

Presentation TCT 2016

Quality-of-Life Measures as Valid Clinical Surrogates and Primary Endpoints in Randomized Trials: Why the Resistance?

Presenter: Roxana Mehran, Pascal Vranckx, John A. Spertus

October 30, 2016

Advertisement

Should Alleviating ISCHEMIA Be the Goal?

Primary Prevention in High Risk Patients II: THEMIS

Primary Prevention In High Risk Patients I: REPRIEVE

Device Design Features and Findings From the Meta-Analysis of Three Randomized Clinical Trials

Perspectives on the ABSORB Randomized Trials: Take-home Messages for the Clinical Practitioner

ILLUMENATE U.S.: A Prospective, Randomized Trial of a Paclitaxel-Coated Balloon vs an Uncoated Balloon for Treatment of Diseased Superficial Femoral and Popliteal Arteries

What Do the Randomized Clinical Trials Tell Us and How Did the FDA Respond?

PARTNER II QUALITY OF LIFE: Health Status Benefits From a Prospective, Randomized Trial of Transcatheter and Surgical Aortic Valve Replacement in Intermediate-Risk Patients With Severe Aortic Stenosis

SENTINEL: A Prospective, Randomized Trial Evaluating Cerebral Protection in Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement

Observational vs Randomized Trials: Strengths and Weaknesses (With Case Examples)

TCT 60: Clinical Outcomes of Absorb Bioresorbable Vascular Scaffold (BVS) in Diabetic and Non-Diabetic Patients: Patient-Level Pooled Analysis From the ABSORB Randomized Trials

TCT 65: Comparative Efficacy and Safety of Coronary Stents in Diabetic Patients With and Without Insulin Treatment: A Pooled Patient Level Analysis From 17 Randomized Trials

NOBLE: A Prospective, Randomized Trial Comparing Biolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients With Left Main Coronary Artery Disease

EXCEL: A Prospective, Randomized Trial Comparing Everolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients With Left Main Coronary Artery Disease

When Are Randomized Trials Not Enough, and Can Observational Data Reliably Inform Comparative Effectiveness Decisions?

Can Propensity and Instrumental Variable Methods Overcome the Limitations of Observational Databases: Lessons From TRANSLATE-ACS

Comparison of Propensity Score Methods and Covariate Adjustment in Observational Studies: Similarities and Differences

Importance of Unmeasured Confounders in Observational Registries: ASCERT and Other Examples

The Smoker's Paradox Revisited: A Five-Year Patient-Level Pooled Analysis of 17 Randomized Controlled Trials

Quality-of-Life Measures as Valid Clinical Surrogates and Primary Endpoints in Randomized Trials: Why the Resistance?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content